approval · primary record
AMIVANTAMAB AND HYALURONIDASE-LPUJ
2 approval events · latest 2026-02-13
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-02-13 |
| Approval events | 2 |
| Brand | RYBREVANT FASPRO |
| Sponsor | JANSSEN BIOTECH |
| Route | SINGLE-USE |
Approval history
2 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-02-13 | FDA | BLA | RYBREVANT FASPRO | JANSSEN BIOTECH | SINGLE-USE |
| 2025-12-17 | FDA | BLA | RYBREVANT FASPRO | JANSSEN BIOTECH | — |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:10.059Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:amivantamab-and-hyaluronidase-lpuj
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab And Hyaluronidase-Lpuj · compound